

Gentium S.p.A.
Form S-8 POS
March 24, 2014

As filed with the Securities and Exchange Commission on March 24, 2014

Registration No. 333-137534
Registration No. 333-146534
Registration No. 333-181171

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-137534

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-146534

Post-Effective Amendment No. 1 to Form S-8 Registration Statement No. 333-181171

FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933

GENTIUM S.p.A.
(Exact name of registrant as specified in its charter)

Republic of Italy (State or other jurisdiction of incorporation or organization)	Not Applicable (I.R.S. Employer Identification No.)
---	--

Piazza XX Settembre 2
22079 Villa Guardia (Como), Italy
+39 031 5373 200
(Address of principal executive offices)

Gentium S.p.A. Amended and Restated 2004 Equity Incentive Plan
Gentium S.p.A. Amended and Restated 2004 Non-Statutory Share Option Plan and Agreement
Gentium S.p.A. 2007 Stock Option Plan
(Full title of plans)

Suzanne Sawochka Hooper
Executive Vice President and General Counsel
Jazz Pharmaceuticals Public Limited Company
c/o Jazz Pharmaceuticals, Inc.
3180 Porter Drive
Palo Alto, CA 94304
(650) 496-3777
(Name, address, including zip code, and telephone number, including area code, of agent for service)

Copies to:

Chadwick L. Mills

Francis Wheeler

Cooley LLP

Cooley LLP

3715 Hanover Street

380 Interlocken Crescent, Suite 900

Palo Alto, CA 94304

Broomfield, CO 80403

(650) 843-5654

(720) 566-4231

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer, accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer (Do not check if a smaller reporting company)

Smaller reporting company

DEREGISTRATION OF SECURITIES

Gentium S.p.A. (the Registrant) is filing this Post-Effective Amendment to its Registration Statements on Form S-8 to withdraw and remove from registration any and all securities that remain unsold or unissued under such Registration Statements identified below pursuant to the Registrant's Amended and Restated 2004 Equity Incentive Plan, Amended and Restated 2004 Non-Statutory Share Option Plan and Agreement and 2007 Stock Option Plan previously registered by the Registrant pursuant to the following registration statements:

Registration Statement on Form S-8 (File No. 333-137534), filed with the Securities and Exchange Commission on September 22, 2006;

Registration Statement on Form S-8 (File No. 333-146534), filed with the Securities and Exchange Commission on October 5, 2007; and

Registration Statement on Form S-8 (File No. 333-181171), filed with the Securities and Exchange Commission on May 4, 2012 (collectively, the Registration Statements).

The securities may be represented by the Registrant's American Depositary Shares (ADSs).

Pursuant to the Tender Offer Agreement, dated as of December 19, 2013, among Jazz Pharmaceuticals Public Limited Company (Jazz Pharmaceuticals), Jazz Pharmaceuticals Italy S.p.A., an Italian *società per azioni* (formerly known as Jazz Pharmaceuticals Italy S.r.l., an Italian *società a responsabilità limitata*) (Purchaser) and a wholly-owned subsidiary of Jazz Pharmaceuticals, and the Registrant (the Tender Offer Agreement), the Purchaser commenced a tender offer (the Offer) to purchase all outstanding ordinary shares of the Registrant, no par value per share (Ordinary Shares), and all outstanding ADS (the ADSs, together with the Ordinary Shares, the Company Shares), each representing one Ordinary Share and evidenced by an American Depositary Receipt, at a purchase price of \$57.00 per Company Share, net to the seller in cash, without interest thereon, less any required withholding taxes. The initial offering period of the Offer expired on January 22, 2014, and the subsequent offering period of the Offer expired on February 20, 2014. The Company Shares acquired in the Offer represent approximately 98% of the outstanding Company Shares. Trading of the ADSs on The NASDAQ Global Market was suspended following the close of trading on March 7, 2014. The Company has filed a Form 25 with the Securities and Exchange Commission to terminate registration of the Company Shares under Section 12(b) of the Securities Exchange Act of 1934, as amended (the Exchange Act) and intends to file a Form 15 to terminate registration of the Company Shares under Section 12(g) of the Exchange Act and suspend its duty to file reports under Sections 13(a) and 15(d) of the Exchange Act.

In accordance with the undertakings made by the Registrant to remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering, the Registrant hereby amends each Registration Statement to withdraw from registration all unsold Company Shares previously registered under the Registration Statements and to terminate the effectiveness of the Registration Statements.

SIGNATURES

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Post-Effective Amendment No. 1 to the Registration Statements to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Villa Guardia (Como) Italy, on the 24th day of March 2014.

GENTIUM, S.p.A.

By: /s/ SALVATORE CALABRESE
Salvatore Calabrese

Chief Financial Officer

Pursuant to the requirements of the Securities Act of 1933, as amended, this Post-Effective Amendment No. 1 to the Registration Statements has been signed by the following persons in the capacities and on the dates indicated:

Signature	Title	Date
/s/ FINTAN KEEGAN	Chairman and Chief Executive Officer	March 24, 2014
Fintan Keegan	<i>(Principal Executive Officer)</i>	
/s/ SALVATORE CALABRESE	Chief Financial Officer <i>(Principal Financial Officer and Principal Accounting Officer)</i>	March 24, 2014
Salvatore Calabrese		
/s/ JOYCE VICTORIA BIGIO	Director	March 24, 2014
Joyce Victoria Bigio		
/s/ SUZANNE SAWOCHKA HOOPER	Director	March 24, 2014
Suzanne Sawochka Hooper		
/s/ IAIN MCGILL	Director	March 24, 2014
Iain McGill		
/s/ ELMAR SCHNEE	Director	March 24, 2014
Elmar Schnee		
/s/ SUZANNE SAWOCHKA HOOPER	Authorized Representative in the United States	March 24, 2014
Suzanne Sawochka Hooper		